Impact of COVID-19 on Business Activities and Performance
First written in FY2020. 1 of 11 entries say "Materialised", first in FY2020. Latest entry: FY2023.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2023MitigatedAnnual report
「The main factors are believed to have been the effects of the information strategy using e-marketing initiatives, the weaker yen from the middle of the current fiscal year onward, and the reduced impact of COVID-19, among others.」
The group returned to operating profitability despite the impact of COVID-19, owing to the reduced impact of the infection, increased overseas sales and e-marketing, among other factors. - FY2023-Q3Return to operating profitability despite the continuing impact of COVID-19Annual report
「During the cumulative third quarter under review, the Group’s revenue substantially exceeded the previous year. Although testing services for LipoSEARCH under the antibody-related business declined, overseas sales volumes of the Group’s core ELISA kits and antibodies increased substantially, and the Group recorded substantial sales of Alzheimer’s-related antibodies in Japan and overseas.」
Although stagnation in LipoSEARCH testing due to the pandemic continued, consolidated sales rose 23.8% year on year on increased overseas sales of ELISA kits and antibodies and higher sales of Alzheimer's-related antibodies, resulting in operating profit of ¥18.887 million. - FY2023-Q2Overseas sales growth and narrower group-wide losses amid the continuing impact of COVID-19Annual report
「In the cumulative second quarter under review, the group's sales exceeded the previous year despite declines in domestic sales of testing services for LipoSEARCH, a blood lipoprotein profiling service in the antibody-related business, and diagnostic reagent services, as overseas sales of the group's core products, ELISA kits and antibodies, increased substantially due to the weaker yen and higher sales volumes.」
Although the pandemic continued to affect LipoSEARCH-related testing and other areas, group-wide sales rose 15.4% year on year due to increased overseas sales of ELISA kits and antibodies driven by the weaker yen and higher sales volumes, while the operating loss narrowed. - FY2023-Q1Overseas sales growth and narrower group-wide losses amid the impact of COVID-19Annual report
「During the cumulative first quarter under review, the Group’s revenue substantially exceeded the previous year, despite concerns about a renewed spread of COVID-19, as the substantial increase in overseas sales of its core diagnostic reagent services more than offset the decline in testing services under the antibody-related business for the blood lipoprotein profiling service LipoSEARCH.」
Although concerns about a renewed spread of COVID-19 and stagnation in LipoSEARCH testing remained, sales rose 25.0% year on year due to increased overseas sales of diagnostic reagents, and the operating loss narrowed. - FY2022-Q2Reagent sales began to recover as research and development activities recoveredAnnual report
「Research and development activities at companies and universities in Japan and overseas began to recover, and signs of recovery emerged, led by sales of core reagent-related EIA measurement kits and antibodies.」
Although concerns about a renewed spread of COVID-19 and restrictions on sales activities remained, research and development activities at companies and universities began to recover, and signs of recovery emerged in sales of EIA measurement kits and antibodies. - FY2022-Q1Business performance improved as research activities recoveredAnnual report
「In the cumulative first quarter under review, while concerns remained about a renewed spread of COVID-19, research and development activities at companies and universities in Japan and overseas began to recover. Signs of recovery emerged, led by sales of the group's core reagent products, particularly ELISA kits.」
Although concerns about a renewed spread of COVID-19 remained, research and development activities at companies and universities in Japan and overseas began to recover, with signs of recovery centered on ELISA kit sales. - FY2021Sales growth and narrower losses across all businesses despite the continuing impactAnnual report
「Under these circumstances, although the group's performance was affected by COVID-19, sales of products utilizing the group's proprietary technologies increased, enabling every business to outperform the previous year.」
Although the impact of COVID-19 continued, sales of products utilizing proprietary technologies enabled every business to outperform the previous year. - FY2021-Q3Group-wide sales growth and narrower losses despite the continuing impactAnnual report
「In the cumulative third quarter under review, the group's sales increased quarter by quarter despite the lack of visibility on an end to the COVID-19 pandemic, enabling the group to outperform the previous year across its overall business performance.」
Although the impact of COVID-19 continued, sales increased quarter by quarter, and group-wide sales rose 6.3% year on year. Business-specific effects remained, including restrictions on promotions for European cosmetics and stagnation in the activities of counterparties in the testing business. - FY2021-Q2Increased orders for specific products despite the continuing impactAnnual report
「Although the group's sales continued to be significantly affected by the spread of COVID-19 from the previous consolidated fiscal year, orders increased under ongoing transactions for specific products during the cumulative second quarter under review.」
Although the impact of COVID-19 on business performance continued, orders increased under ongoing transactions for specific products, and group-wide sales rose 7.4% year on year. - FY2021-Q1WorsenedAnnual report
「Revenue from research reagents, including the Company’s core EIA kits and antibodies, declined by approximately 30% year on year as customers in Japan and overseas curtailed their research and business activities due to the spread of COVID-19.」
The impact of COVID-19 continued from the previous consolidated fiscal year, and sales of major research reagent products declined by approximately 30% year on year. The company explained that a recovery to the previous year's sales level would be difficult because of stagnation in business partners' activities and restrictions on sales activities. - FY2020MaterialisedAnnual report
「The spread of COVID-19 affected both sales and procurement because customers, suppliers and other business locations temporarily suspended operations.」
The spread of COVID-19 actually resulted in delays in research activities, temporary closures by customers and suppliers, lower sales, a halt to overseas business negotiations and delays in the resumption of sales in China.